Compare CTRN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTRN | PRTA |
|---|---|---|
| Founded | 1946 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.5M | 526.7M |
| IPO Year | 2005 | 2013 |
| Metric | CTRN | PRTA |
|---|---|---|
| Price | $63.92 | $8.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $52.00 | $19.00 |
| AVG Volume (30 Days) | 238.4K | ★ 604.5K |
| Earning Date | 06-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.14 | N/A |
| EPS | ★ 0.91 | 0.60 |
| Revenue | ★ $819,962,000.00 | $814,000.00 |
| Revenue This Year | $8.81 | $1,111.38 |
| Revenue Next Year | $8.35 | N/A |
| P/E Ratio | $70.39 | ★ $14.11 |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $28.45 | $6.24 |
| 52 Week High | $66.38 | $11.80 |
| Indicator | CTRN | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 66.29 | 42.31 |
| Support Level | $42.10 | $8.36 |
| Resistance Level | $66.38 | $10.29 |
| Average True Range (ATR) | 2.94 | 0.45 |
| MACD | 0.33 | -0.11 |
| Stochastic Oscillator | 81.43 | 30.12 |
Citi Trends Inc is a differentiated off-price value retailer known for trendy fashions, great brands and amazing prices. It is the off-price retailer specifically focused on Black customers, delivering the styles, brands, and trends at amazing prices that resonate with its primary and secondary customers. Its product offering is Women's, Men's and Children's apparel, family footwear, accessories and products for the home, with a three-tiered mix of product. At the opening price point, the company offers value-focused basics for its budget-conscious customers.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.